Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor

Lymphangioleiomyomatosis (LAM) is a rare metastatic cystic lung disease due to a mutation in a TSC tumor suppressor, resulting in hyperactive mTOR growth pathways. Sirolimus (rapamycin), an allosteric mTORC1 inhibitor, is a therapeutic option for women with LAM but it only maintains lung volume duri...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Jilly F., Rue, Ryan W., Mukhitov, Alexander R., Obraztsova, Kseniya, Smith, Carly J., Krymskaya, Vera P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022412/
https://www.ncbi.nlm.nih.gov/pubmed/31878201
http://dx.doi.org/10.3390/biom10010028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022412/
https://www.ncbi.nlm.nih.gov/pubmed/31878201
http://dx.doi.org/10.3390/biom10010028

Ejemplares similares